S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.80 (-5.00%)
BABA   68.47 (-0.60%)
T   16.31 (-0.12%)
F   12.05 (-0.08%)
MU   106.85 (-4.54%)
GE   147.29 (-3.69%)
CGC   7.93 (+1.28%)
DIS   111.61 (-0.73%)
AMC   3.20 (+9.59%)
PFE   25.77 (+1.50%)
PYPL   61.87 (-0.37%)
XOM   119.58 (+0.89%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.80 (-5.00%)
BABA   68.47 (-0.60%)
T   16.31 (-0.12%)
F   12.05 (-0.08%)
MU   106.85 (-4.54%)
GE   147.29 (-3.69%)
CGC   7.93 (+1.28%)
DIS   111.61 (-0.73%)
AMC   3.20 (+9.59%)
PFE   25.77 (+1.50%)
PYPL   61.87 (-0.37%)
XOM   119.58 (+0.89%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.80 (-5.00%)
BABA   68.47 (-0.60%)
T   16.31 (-0.12%)
F   12.05 (-0.08%)
MU   106.85 (-4.54%)
GE   147.29 (-3.69%)
CGC   7.93 (+1.28%)
DIS   111.61 (-0.73%)
AMC   3.20 (+9.59%)
PFE   25.77 (+1.50%)
PYPL   61.87 (-0.37%)
XOM   119.58 (+0.89%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.80 (-5.00%)
BABA   68.47 (-0.60%)
T   16.31 (-0.12%)
F   12.05 (-0.08%)
MU   106.85 (-4.54%)
GE   147.29 (-3.69%)
CGC   7.93 (+1.28%)
DIS   111.61 (-0.73%)
AMC   3.20 (+9.59%)
PFE   25.77 (+1.50%)
PYPL   61.87 (-0.37%)
XOM   119.58 (+0.89%)
Free Trial
NASDAQ:GLMD

Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)
Free GLMD Stock Alerts
$0.38
0.00 (-0.05%)
(As of 12:13 PM ET)
Compare
Today's Range
$0.37
▼
$0.38
50-Day Range
$0.30
▼
$0.42
52-Week Range
$0.26
▼
$7.80
Volume
8,066 shs
Average Volume
187,981 shs
Market Capitalization
$1.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media
GLMD stock logo

About Galmed Pharmaceuticals Stock (NASDAQ:GLMD)

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

GLMD Stock Price History

GLMD Stock News Headlines

April 19, 2024 | americanbankingnews.com
JanOne (NASDAQ:JAN) and Galmed Pharmaceuticals (NASDAQ:GLMD) Head-To-Head Analysis
April 16, 2024 | americanbankingnews.com
Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com
April 19, 2024 | Insiders Exposed (Ad)
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
April 13, 2024 | fool.com
Galmed Pharmaceuticals (NASDAQ: GLMD)
April 10, 2024 | investorplace.com
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
April 4, 2024 | prnewswire.com
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
March 15, 2024 | markets.businessinsider.com
Galmed Granted European Patent For Use Of Aramchol-Resmetirom To Treat NASH/MASH, Liver Fibrosis
March 15, 2024 | prnewswire.com
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
April 19, 2024 | Insiders Exposed (Ad)
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
February 13, 2024 | uk.finance.yahoo.com
Galmed Pharmaceuticals Ltd (GPH.BE)
January 3, 2024 | uk.finance.yahoo.com
Galmed Pharmaceuticals Ltd. (GPH.F)
November 20, 2023 | finance.yahoo.com
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
November 4, 2023 | morningstar.com
Galmed Pharmaceuticals Ltd GLMD
September 26, 2023 | finance.yahoo.com
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
August 3, 2023 | nasdaq.com
Galmed Pharmaceuticals (GLMD) Price Target Increased by 300.00% to 4.08
July 14, 2023 | marketwatch.com
Galmed Pharma Shares Drop 30% After Public Offering Prices
July 14, 2023 | seekingalpha.com
Galmed shares slump on pricing discounted stock and warrants offering
July 14, 2023 | finance.yahoo.com
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
July 13, 2023 | investorplace.com
Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?
July 10, 2023 | finance.yahoo.com
Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC
July 3, 2023 | bizjournals.com
Madrigal begins process seeking OK for multibillion-dollar — yet elusive — NASH drug
June 3, 2023 | benzinga.com
Galmed Pharmaceuticals Stock (NASDAQ:GLMD), Insider Trading Activity
June 1, 2023 | finanznachrichten.de
Galmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
June 1, 2023 | msn.com
Recap: Galmed Pharmaceuticals Q1 Earnings
June 1, 2023 | finance.yahoo.com
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
May 17, 2023 | thestreet.com
Why Galmed Pharmaceuticals (GLMD) Stock Is Surging Today
May 11, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (GLMD) and Haemonetics (HAE)
See More Headlines
Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
6/01/2023
Today
4/19/2024
Next Earnings (Estimated)
6/06/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GLMD
CUSIP
N/A
CIK
1595353
Web
www.galmedpharma.com
Phone
(723) 693-8448
Fax
972-3693-8447
Employees
4
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,910,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-53.29%
Return on Assets
-44.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.81
Quick Ratio
4.81

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.75 per share
Price / Book
0.14

Miscellaneous

Outstanding Shares
5,050,000
Free Float
4,046,000
Market Cap
$1.90 million
Optionable
Not Optionable
Beta
0.87
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Allen Baharaff (Age 59)
    Co-Founder, President, CEO & Chairman
    Comp: $803.5k
  • Mr. Doron Cohen (Age 57)
    Chief Financial Officer
    Comp: $175.33k
  • Mr. Guy Nehemya (Age 39)
    COO & Data Protection Officer
    Comp: $235.56k
  • Mr. Yohai Stenzler CPA (Age 41)
    Chief Accounting Officer
    Comp: $239.48k
  • Dr. Liat Hayardeny (Age 57)
    Chief Scientific Officer
    Comp: $125.24k
  • Ms. Yael Hollander (Age 41)
    Vice President of Legal Affairs & Strategy
    Comp: $134.21k
  • Ms. Shani Ganon
    Human Resources Manager
  • Dr. Tali Gorfine (Age 54)
    Medical Consultant
    Comp: $202.76k

Key Competitors

View All Competitors

GLMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Galmed Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GLMD shares.
View GLMD analyst ratings or view top-rated stocks.

How have GLMD shares performed in 2024?

Galmed Pharmaceuticals' stock was trading at $0.4550 at the beginning of 2024. Since then, GLMD stock has decreased by 16.8% and is now trading at $0.3785.
View the best growth stocks for 2024 here.

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 39,200 shares, an increase of 532.3% from the March 15th total of 6,200 shares. Based on an average trading volume of 202,100 shares, the days-to-cover ratio is currently 0.2 days. Approximately 1.1% of the company's shares are short sold.
View Galmed Pharmaceuticals' Short Interest.

When is Galmed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 6th 2024.
View our GLMD earnings forecast.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) released its quarterly earnings data on Thursday, June, 1st. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, topping analysts' consensus estimates of ($1.50) by $0.41.

When did Galmed Pharmaceuticals' stock split?

Galmed Pharmaceuticals shares reverse split before market open on Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLMD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
1970’s computer coder issues shocking A.I. warning
TradeSmith